<DOC>
	<DOCNO>NCT01805570</DOCNO>
	<brief_summary>The aim RAPID study evaluate superiority rapid onset action Ticagrelor 360 mg LD versus Prasugrel 60 mg LD , 50 patient STEMI ( ST segment elevation myocardial infarction ) undergo PPCI bivalirudin monotherapy . Secondary study aim find clinical predictor high residual platelet reactivity first hour novel oral antiplatelet agent LD .</brief_summary>
	<brief_title>Rapid Activity Platelet Inhibitor Drugs Study 2</brief_title>
	<detailed_description>50 consecutive patient STEMI undergo PPCI bivalirudin ( GP IIb/IIIa allow ) randomize receive Prasugrel ( n= 25 ) Ticagrelor ( n= 25 ) PPCI ( primary percutaneous coronary intervention ) open label fashion . The load dose Prasugrel 60 mg , load dose Ticagrelor 360 mg 25 patient . The load dose perform soon possible Emergency Room Cath Lab . In case vomit first hour drug load dose new reduce loading dose administer ( 30 mg Prasugrel 180 mg Ticagrelor ) . All intervention perform femoral approach accord current standard . The use thrombectomy infarct-related artery stenting , everolimus elute stent closure device strongly encourage . Bivalirudin administer bolus 0.75 mg/kg follow 1.75 mg/kg/h infusion PCI . After PCI ( percutaneous coronary intervention ) reduce bivalirudin infusion 0.25 mg/kg/h 4 hour allow . Dual antiplatelet therapy ( 100 mg aspirin associate 5 10 mg Prasugrel 180 mg Ticagrelor ) recommend 12 month . Residual platelet reactivity assess patient baseline ( time LD ) , 1 , 2 , 4 12 hour point-of-care test VerifyNow bedside available Intensive cardiac care Unit . High residual platelet reactivity define Platelet Reactivity Units ( PRU ) &gt; 240 VerifyNow . At time point , Aspirin Reactivity Units ( ARU ) VerifyNow also assess . Follow-up perform outpatient visit telephone interview 6 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients present within 12 hour onset symptom STEMI ( ST segment elevation myocardial infarction ) Informed , write consent Age &lt; 18 year Age &gt; 75 year Active bleeding ; bleed diathesis ; coagulopathy Increased risk bradycardiac event History gastrointestinal genitourinary bleeding &lt; 2 month Major surgery last 6 week History intracranial bleed structural abnormality Suspected aortic dissection Any previous TIA ( transient ischemic attack ) /stroke Any condition may put patient risk influence study result investigator 's opinion ( severe haemodynamic instability , know malignancy comorbid condition life expectancy &lt; 1 year ) Administration week index event clopidogrel , ticlopidine , prasugrel , ticagrelor , thrombolytic , bivalirudin , lowmolecular weight heparin fondaparinux . Concomitant oral IV therapy strong CYP3A inhibitor strong CYP3A inducer , CYP3A narrow therapeutic window Known relevant hematological deviation : Hb &lt; 10 g/dl , Platelet count &lt; 100x10^9/l Use coumadin derivative within last 7 day Chronic therapy prasugrel ticagrelor Known severe liver disease , severe renal failure Known allergy study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>platelet inhibitor</keyword>
	<keyword>ST-segment Elevation</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>stent</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
</DOC>